Pancreatic Cancer Research

ResearcherUniversity Health NetworkNo recent work listed

Peter W. T. Pisters

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111930765. Sources: ClinicalTrials.gov.

Their work

Papers
30 (first author 1, last author 3)
Trials
2
Grants
0
Labs led
1
Collaborators
77
Papers, trials and grants by year

2002: 1 trial · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: 1 trial · 2010: none · 2011: 4 papers · 2012: 14 papers · 2013: 5 papers · 2014: 3 papers · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper

Papers 30

  1. Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial. Co-author DOI 10.1245/s10434-019-07685-1↗
  2. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. Co-author DOI 10.1007/s11605-016-3265-1↗
  3. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/pas.0000000000000491↗
  4. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer. Co-author DOI 10.1245/s10434-014-4192-6↗
  5. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cance… Co-author DOI 10.1007/s11605-013-2374-3↗
  6. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and surviva… Co-author DOI 10.1007/s11605-013-2412-1↗
  7. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. Co-author DOI 10.1111/hpb.12154↗
  8. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2012.09.001↗
  9. Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience. Co-author DOI 10.1097/coc.0b013e31823a53ce↗
  10. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal… Co-author DOI 10.1111/his.12234↗
  11. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Co-author DOI 10.1245/s10434-013-2886-9↗
  12. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Co-author DOI 10.1245/s10434-013-2889-6↗
  13. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Co-author DOI 10.1001/archsurg.2011.2281↗
  14. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Co-author DOI 10.1002/cncr.26243↗
  15. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcom… Co-author DOI 10.1002/cncr.26651↗
  16. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with n… Co-author DOI 10.1002/cncr.26717↗
  17. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Co-author DOI 10.1002/cncr.27636↗
  18. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. Co-author DOI 10.1007/s11605-011-1748-7↗
  19. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. Co-author DOI 10.1007/s11605-012-1912-8↗
  20. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Co-author DOI 10.1016/j.anndiagpath.2011.08.005↗
  21. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. Co-author DOI 10.1016/j.jamcollsurg.2012.05.015↗
  22. Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreat… Co-author DOI 10.1097/pas.0b013e318240c1c0↗
  23. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/pas.0b013e31824104c5↗
  24. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. Co-author DOI 10.1111/j.1477-2574.2012.00445.x↗
  25. Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-12-0223↗
  26. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therap… Co-author DOI 10.1245/s10434-011-2211-4↗
  27. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACO… Last author DOI 10.1093/annonc/mdq384↗
  28. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 t… Last author DOI 10.1245/s10434-010-1282-y↗
  29. Borderline resectable pancreatic cancer: what have we learned and where do we go from here? First author DOI 10.1245/s10434-010-1460-y↗
  30. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Last author DOI 10.1245/s10434-011-1847-4↗

Trials 2

  1. Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Study chair NCT00733746↗
  2. Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer Study chair NCT00068575↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 27 shared papers, 2011–2017 · strength 0.86
  2. Jason B. Fleming · 25 shared papers, 2011–2017 · strength 0.80
  3. Jeffrey E. Lee · 25 shared papers, 2011–2017 · strength 0.80
  4. Robert A. Wolff · 18 shared papers, 2011–2019 · strength 0.62
  5. Huamin Wang · 17 shared papers, 2012–2017 · strength 0.55
  6. Gauri Rajani Varadhachary · 17 shared papers, 2011–2017 · strength 0.53
  7. James L. Abbruzzese · 13 shared papers, 2012–2017 · strength 0.40
  8. Jean‐Nicolas Vauthey · 12 shared papers, 2012–2015 · strength 0.37
  9. Christopher H. Crane · 11 shared papers, 2011–2017 · strength 0.36
  10. Douglas B. Evans · 6 shared papers, 2011–2019 · strength 0.24
  11. Hua Wang · 8 shared papers, 2012–2015 · strength 0.24
  12. Mitchell C. Posner · 5 shared papers, 2011–2019 · strength 0.20
  13. Deyali Chatterjee · 6 shared papers, 2012–2015 · strength 0.19
  14. Eric Peter Tamm · 4 shared papers, 2012–2019 · strength 0.18
  15. Ching-Wei David Tzeng · 5 shared papers, 2012–2014 · strength 0.16
  16. Aparna Balachandran · 5 shared papers, 2012–2014 · strength 0.14
  17. Jeannelyn Santiano Estrella · 4 shared papers, 2012–2015 · strength 0.13
  18. Hedy Lee Kindler · 2 shared papers, 2013–2019 · strength 0.10
  19. Jordan D. Berlin · 2 shared papers, 2013–2019 · strength 0.10
  20. Nipun B. Merchant · 2 shared papers, 2011–2019 · strength 0.10
  21. Priya Bhosale · 3 shared papers, 2012–2017 · strength 0.10
  22. Ross Allen Abrams · 3 shared papers, 2011–2013 · strength 0.10
  23. Eileen Mary O'Reilly · 2 shared papers, 2011–2019 · strength 0.10
  24. Vincent J. Picozzi · 3 shared papers, 2011–2013 · strength 0.10
  25. Gauri A Varadhachary · 3 shared papers, 2012–2014 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.